Cédric Szyndralewiez, Head of Non-Clinical and Early Development, will be responsible for the  regulatory clinical development of Augustine Tx portfolio drug candidates.

Cédric has 25 years of experience in drug research and development within mid-size pharmaceutical (Serono) and biotech companies (GenKyotex/Calliditas Therapeutics, Pherecydes) contributing and leading the discovery and development of several modalities (small molecules, phages) across a wide range of therapeutic indications, including multiple sclerosis, pain, nonalcoholic steatohepatitis, primary biliary cholangitis (PBC), Idiopathic pulmonary fibrosis, angiogenesis, and cancer.
In particular, Cédric made major contributions to the identification and clinical development of the First-in-Class NOX1/4 inhibitor Setanaxib, which is currently in Phase 3 in patients suffering from Primary biliary cholangitis and in Phase 2 in patients suffering from head and neck cancer.

In early 2022, Cédric finally joined Pherecydes Pharma, a biotech specializing in phage therapy, as Global and Clinical Project Manager to support the company's clinical development program in antibiotic-resistant infections.

Cédric holds a master's degree in pharmacology from the University of Lyon and the Veterinary School of Lyon. He is the co-author of 30 peer-reviewed scientific publications.